Jane Street’s Telix Pharmaceuticals TLX Stock Holding History

Jane Street’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-33,389	Closed	-$385K	–	13310
2026 Q2	$385K	Buy	+33,389	New	+$340K	﹤0.01%	8622
2026 Q1	–	Sell	-40,042	Closed	-$300K	–	13342
2025 Q4	$300K	Sell	40,042 -32,950	-45%	-$317K	﹤0.01%	8840
2025 Q3	$699K	Buy	72,992 +37,889	+108%	+$464K	﹤0.01%	7099
2025 Q2	$564K	Buy	+35,103	New	+$589K	﹤0.01%	6693

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Portland Investment Counsel Burlington, Ontario, Canada $339M AUM 1.43% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Brinker Capital Investments Berwyn, Pennsylvania $17.5B AUM 20.48% 1-Year Est. Return

Jane Street's TLX Position: Q3 2026 in Review

Jane Street sold out of Telix Pharmaceuticals (TLX) in Q3 2026, closing a stake of 33,389 shares — an estimated $385K sold.

Jane Street first reported a position in TLX in Q2 2025 and held it in 4 quarters. The position peaked at $699K in Q3 2025. 50 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

Jane Street reported no remaining Telix Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Jane Street sold 33,389 Telix Pharmaceuticals shares in Q3 2026, an estimated $385K.
Jane Street first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Jane Street's Telix Pharmaceuticals position peaked at $699K in Q3 2025.
50 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.